Abstract
Ovarian cancer currently ranks as the fourth most common cancer. This cancer is metastatic in nature and making it more challenging to manage. Prostate cancer is the one of the major causes of disease and death among men. Approximately 1.6 million men are diagnosed with prostate cancer. Rucaparib, a poly-ADP ribose polymerase inhibitor has been approved by United States Food and Drug Administration for management of ovarian cancer and prostate cancer. Rucaparib was approved by US Food and Drug Administration in the year 2016 for the treatment of ovarian cancer and 2020 for the treatment of prostate cancer. To assess the potential association between rucaparib and the identified signals, a disproportionality analysis of spontaneous reports is being conducted. Reports were taken from FAERS data base and retrospective case/non case study was conducted. Reporting Odds ratio (ROR), Relative Reporting Ratio (RRR), Chi Squared Value (χ2) and Proportional Reporting Ratio (PRR) and Drug Event (DE) were used to perform disproportionality analysis. 144 signals were considered as positive adverse drug reactions using the criteria χ2 >4, PRR >2, ROR >2 and DE ≥ 3. Through disproportionality analysis of the FAERS data, signal was identified between the signals-increased prostate specific antigen, decreased serum magnesium levels, decreased glomerular filtration rates, blood iron decreased and vitamin d decreased and rucaparib. The current investigation indicated that rucaparib may increase the incidence of the identified signals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
